ValiRx plc (GB:VAL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ValiRx plc, a life sciences company specializing in cancer therapeutics and women’s health, announces a change in leadership as Dr Mark Eccleston takes on the role of CEO following Dr Suzanne Dilly’s departure. Dr Eccleston brings over 30 years of experience and a history of successful scientific and commercial ventures, including the founding of a US listed biomarker company, to his new position. The company expresses its commitment to advancing its drug development strategy and creating long-term shareholder value under Eccleston’s guidance.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
